Authors

Joe M. O'Sullivan, MD, FRCPI, FFRRSCI, FRCR, Queens University Belfast

Latest:

Dr. O'Sullivan on Safety Profile of Radium-223

Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queenâ€™s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.

Joe OSullivan, MD, FRCPI, FFRRCSI, FRCR, The Northern Ireland Cancer Centre, Belfast City Hospital

Joe OSullivan, MD, Queen's University

Joel Neal, MD

Latest:

Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Therapy for ALK+ NSCLC

Joel Neal, MD, an assistant professor of medicine and oncology at Stanford Medicine, discusses whether, if approved by the FDA, alectinib (Alecensa) will become the frontline standard of care for patients with ALK-positive non–small cell lung cancer (NSCLC).

Joel Neal, MD, PhD

Joel Neal, MD, PhD, is a professor of medicine in the Division of Oncology at the Stanford Cancer Institute at Stanford University

Latest:

FDA Approval Insights: Taletrectinib in ROS1+ Advanced/Metastatic NSCLC: With Joel Neal, MD, PhD; and Christian Rolfo, MD, PhD

Drs Neal and Rolfo discuss the significance of the FDA approval of taletrectinib for the treatment of locally advanced or metastatic, ROS1-positive NSCLC.

Joel Silver, MD

Latest:

Dr. Silver Talks About Advances in Treatment of Hematological Cancers

Joel Silver, MD, a medical oncologist and a member of the board of directors of Regional Cancer Care Associates, discusses the progress being made in the treatment of hematological cancers, especially in multiple myeloma.

Joel Stettler, BSN, RN, OCN

Latest:

Joel Stettler on Procedures for Fall-Risk Patients

Joel Stettler, BSN, RN, OCN, Moffitt Cancer Center, discusses procedures implemented at his institution for patients who are at risk for falls.Â

Johan F. Vansteenkiste, MD, PhD, Leuven University Hospital

Johan Vansteenkiste, MD,PhD

Latest:

Dr. Johan Vansteenkiste on Atezolizumab in NSCLC

Johan F. Vansteenkiste, MD, PhD, professor of Internal Medicine at Katholieke Universiteit Leuven, Belgium, discusses the primary analysis of the phase II POPLAR study, which looked at atezolizumab versus docetaxel in patients with nonâ€“small cell lung cancer (NSCLC).

Johann de Bono, PhD, MB, ChB, Institute of Cancer Research, Royal Marsden Hospital

Johanna Bendell, MD

Latest:

Dr. Bendell Discusses a Phase III Study of Apatinib in Gastric Cancer

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses a randomized phase III placebo-controlled trial that explored apatinib as a treatment for patients with advanced gastric cancer.

Johanna Bendell, MD, Sarah Cannon

Johanna Bendell, MD, Sarah Cannon Cancer Institute

Latest:

Global Updates in Advanced Gastric Cancer from ESMO 2020

Johanna Bendell, MD, The Sarah Cannon Research Institute

Johanna C. Bendell, MD

Latest:

Dr. Bendell on the Next Steps Following Progression on Immunotherapy in MSI-H CRC

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).

Johanna C Bendell, MD, Sarah Cannon Research Institute

Johannes Smit, MD, PhD Radboud University Nijmegen Medical Center

John A. Abraham, MD, FACS

Latest:

Dr. Abraham on Surgical Improvements in TGCT

John A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.

John A. Abraham, MD, Rothman Orthopaedic Institute